Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival.

See related article by Tolmeijer et al., p. xxx

This content is only available via PDF.
You do not currently have access to this content.